NASDAQ:AIFC ALT5 Sigma Q2 2026 Earnings Report $0.56 0.00 (0.00%) As of 09/4/2026 04:00 PM Eastern ProfileEarnings HistoryForecast ALT5 Sigma EPS ResultsActual EPS$0.42Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AALT5 Sigma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AALT5 Sigma Announcement DetailsQuarterQ2 2026Date8/17/2026TimeAfter Market ClosesConference Call DateMonday, August 17, 2026Conference Call Time8:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) ALT5 Sigma Earnings HeadlinesTrump-linked fintech firm AI Financial sells unit to PrimeDeltaAugust 9, 2026 | msn.comTrump-linked fintech firm AI Financial sells unit to Prime DeltaAugust 7, 2026 | msn.comFeds Say Your Cash Isn’t Property—Can They Take It?The Department of Justice recently argued in court that cash may not qualify as legal property. That raises new questions about how protected everyday bank accounts and retirement savings really are.September 8 at 1:00 AM | Priority Gold (Ad)Trump-linked fintech AI Financial sells unit to Prime DeltaAugust 7, 2026 | reuters.comTrump Crypto Tie-Up Fueled Family Windfall, Investor LossesJuly 30, 2026 | finance.yahoo.comPerpetuals.com ends acquisition talks with Trump-linked crypto firmJuly 14, 2026 | reuters.comSee More ALT5 Sigma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ALT5 Sigma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ALT5 Sigma and other key companies, straight to your email. Email Address About ALT5 SigmaALT5 Sigma (NASDAQ:AIFC) Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.View ALT5 Sigma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/31 - 09/04Why Guidewire’s Post-Earnings Plunge May Not LastPalo Alto vs. Zscaler: Which Cybersecurity Stock Looks Stronger After Earnings?Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key SignalLululemon’s Earnings Beat Hid a Bigger Problem for Its Turnaround Story3 Stocks With September Catalysts Investors Shouldn’t IgnoreParsons’ Pullback May Give Defense and Infrastructure Investors a Second Look Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
